HDL protects against ischemia reperfusion injury by preserving mitochondrial integrity

Atherosclerosis

Volumn 228, Issue 1, 2013, Pages 110-116

  Frias, Miguel A ^a,b   Pedretti, Sarah ^b   Hacking, Damian ^b   Somers, Sarin ^b   Lacerda, Lydia ^b   Opie, Lionel H ^b   James, Richard W ^a   Lecour, Sandrine ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

HDL; Ischemia reperfusion injury; MPTP; SAFE pathway; STAT3; TNF

Indexed keywords

HIGH DENSITY LIPOPROTEIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART PROTECTION; MALE; MITOCHONDRIAL PERMEABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY;

ANIMALS; CELL SURVIVAL; CHOLESTEROL, HDL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOCHONDRIA; MITOCHONDRIAL MEMBRANES; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876795828     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.02.003     Document Type: Article

References (28)

1. Barter P.J., Rye K.A. High density lipoproteins and coronary heart disease. Atherosclerosis 1996, 121:1-12.
2. Nofer J.R., Kehrel B., Fobker M., Levkau B., Assmann G., von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 2002, 161:1-16.
3. Calabresi L., Rossoni G., Gomaraschi M., Sisto F., Berti F., Franceschini G. High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ Res 2003, 92:330-337.
4. Theilmeier G., Schmidt C., Herrmann J., et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 2006, 114:1403-1409.
5. Tao R., Hoover H.E., Honbo N., et al. High-density lipoprotein determines adult mouse cardiomyocyte fate after hypoxia-reoxygenation through lipoprotein-associated sphingosine 1-phosphate. Am J Physiol Heart Circ Physiol 2010, 298:H1022-H1028.
6. Frias M.A., Lang U., Gerber-Wicht C., James R.W. Native and reconstituted HDL protect cardiomyocytes from doxorubicin-induced apoptosis. Cardiovasc Res 2010, 85:118-126.
7. Lecour S. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway?. J Mol Cell Cardiol 2009, 47:32-40.
8. Lacerda L., Somers S., Opie L.H., Lecour S. Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc Res 2009, 84:201-208.
9. Frias M.A., James R.W., Gerber-Wicht C., Lang U. Native and reconstituted HDL activate Stat3 in ventricular cardiomyocytes via ERK1/2: role of sphingosine-1-phosphate. Cardiovasc Res 2009, 82:313-323.
10. Halestrap A.P., Clarke S.J., Khaliulin I. The role of mitochondria in protection of the heart by preconditioning. Biochim Biophys Acta 2007, 1767:1007-1031.
11. Wegrzyn J., Potla R., Chwae Y.J., et al. Function of mitochondrial Stat3 in cellular respiration. Science 2009, 323:793-797.
12. Boengler K., Hilfiker-Kleiner D., Heusch G., Schulz R. Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. Basic Res Cardiol 2010, 105:771-785.
13. Smith C.C., Dixon R.A., Wynne A.M., et al. Leptin-induced cardioprotection involves JAK/STAT signaling that may be linked to the mitochondrial permeability transition pore. Am J Physiol Heart Circ Physiol 2010, 299:H1265-H1270.
14. Smith R.M., Suleman N., Lacerda L., et al. Genetic depletion of cardiac myocyte STAT-3 abolishes classical preconditioning. Cardiovasc Res 2004, 63:611-616.
15. Marino M.W., Dunn A., Grail D., et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A 1997, 94:8093-8098.
16. James R.W., Proudfoot A., Pometta D. Immunoaffinity fractionation of high-density lipoprotein subclasses 2 and 3 using anti-apolipoprotein A-I and A-II immunosorbent gels. Biochim Biophys Acta 1989, 1002:292-301.
17. Lecour S., Suleman N., Deuchar G.A., et al. Pharmacological preconditioning with tumor necrosis factor-alpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). Circulation 2005, 112:3911-3918.
18. Lewin T.M., de Jong H., Schwerbrock N.J., et al. Mice deficient in mitochondrial glycerol-3-phosphate acyltransferase-1 have diminished myocardial triacylglycerol accumulation during lipogenic diet and altered phospholipid fatty acid composition. Biochim Biophys Acta 2008, 1781:352-358.
19. Morel S., Frias M.A., Rosker C., James R.W., Rohr S., Kwak B.R. The natural cardioprotective particle HDL modulates connexin43 gap junction channels. Cardiovasc Res 2012, 93:41-49.
20. Lamont K.T., Somers S., Lacerda L., Opie L.H., Lecour S. Is red wine a SAFE sip away from cardioprotection? Mechanisms involved in resveratrol- and melatonin-induced cardioprotection. J Pineal Res 2011, 50:374-380.
21. Fuglesteg B.N., Suleman N., Tiron C., et al. Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion. Basic Res Cardiol 2008, 103:444-453.
22. Lecour S., Smith R.M., Woodward B., Opie L.H., Rochette L., Sack M.N. Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol 2002, 34:509-518.
23. Lacerda L., McCarthy J., Mungly S.F., et al. TNFα protects cardiac mitochondria independently of its cell surface receptors. Basic Res Cardiol 2010, 105:751-762.
24. Heusch G., Musiolik J., Gedik N., Skyschally A. Mitochondrial STAT3 activation and cardioprotection by ischemic postconditioning in pigs with regional myocardial ischemia/reperfusion. Circ Res 2011, 109:1302-1308.
25. Szczepanek K., Chen Q., Derecka M., et al. Mitochondrial-targeted Signal transducer and activator of transcription 3 (STAT3) protects against ischemia-induced changes in the electron transport chain and the generation of reactive oxygen species. J Biol Chem 2011, 286:29610-29620.
26. Somers S.J., Frias M., Lacerda L., Opie L.H., Lecour S. Interplay between SAFE and RISK pathways in sphingosine-1-phosphate-induced cardioprotection. Cardiovasc Drugs Ther 2012, 26:227-237.
27. Zhang B., Tomura H., Kuwabara A., et al. Correlation of high density lipoprotein (HDL)-associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins. Atherosclerosis 2005, 178:199-205.
28. Frias M.A., Lecour S., James R.W., Pedretti S. High density lipoprotein/sphingosine-1 phosphate-induced cardioprotection: role of STAT3 as part of the SAFE pathway. JAK/STAT 2012, 1:92-100.